Mouse skin carcinomas arise from a small subpopulation of benign papillomas with an increased risk of malignant conversion. These papillomas arise with limited stimulation by tumor promoters, appear rapidly, and do not regress, suggesting that they differ in growth properties from the majority of benign tumors. The transforming growth factor .3 proteins are expressed in the epidermis and are growth inhibitors for mouse keratinocytes in vitro; altered TGF-18 expression could influence the growth properties of high-risk papillomas. Normal epidermis, tumor promotertreated epidermis, and skin papillomas at low risk for malignant conversion express TGF-.81 in the basal cell compartment and TGF-,82 in the suprabasal strata. In low-risk tumors, 90% ofthe proliferating cells are confined to the basal compartment.
.3 proteins are expressed in the epidermis and are growth inhibitors for mouse keratinocytes in vitro; altered TGF-18 expression could influence the growth properties of high-risk papillomas. Normal epidermis, tumor promotertreated epidermis, and skin papillomas at low risk for malignant conversion express TGF-.81 in the basal cell compartment and TGF-,82 in the suprabasal strata. In low-risk tumors, 90% ofthe proliferating cells are confined to the basal compartment.
In contrast, the majority of high-risk papillomas are devoid of both TGF-,B1 and TGF-f82 as soon as they arise; these tumors have up to 40% of the proliferating cells in the suprabasal layers. Squamous cell carcinomas are also devoid of TGF-3, suggesting that they arise from the TGF--deflcient high-risk papillomas. In some high-risk papillomas, TGF-(31 loss can occur first and correlates with basal cell hyperproliferation, while TGF-,32 loss correlates with suprabasal hyperproliferation. Similarly, TGF-(31-null transgenic mice, which express wild-type levels of TGF-182 in epidernds but no TGF-131 in the basal layer, have a hyperproliferative basal cell layer without suprabasal proliferation. In tumors, loss ofTGF-I is controlled at the posttranscriptional level and is associated with expression of keratin 13, a documented marker of malignant progression. These results show that TGF-.3 expression and function are compartmentafized in epidermis and epidermal tumors and that loss of TGF-(8 is an early, biologically relevant risk factor for malignant progression.
In multistage chemical carcinogenesis of the mouse epidermis, malignant conversion of a benign papilloma to a squamous cell carcinoma is a rare event (1) . While most papillomas and carcinomas generated by initiation with 7,12- dimethylbenz[a]anthracene (DMBA) have an A --T mutation at codon 61 of the Ha-ras allele (2, 3) , there is evidence for subpopulations of papillomas with distinct risks for malignant conversion. Standard protocols utilizing DMBA initiation and continuous promotion with phorbol 12-myristate 13 -acetate (PMA) produce a large number of papillomas, the majority of which arise after 10 weeks and have a malignant conversion frequency of 3-5% (4). Many of these tumors are promoter-dependent and regress rapidly when PMA treatment is terminated (5) . In contrast, DMBA initiation followed by 5 weeks of PMA promotion, or continuous promotion with the weak promoter mezerein, yields fewer papillomas, which arise within 6-8 weeks, do not regress in the absence of promotion, and have a conversion frequency of 15-25% (4). This suggests that most carcinomas arise from a small population of papillomas that have relatively autonomous growth properties from the earliest stages.
Changes in growth factor expression could contribute to the altered growth properties of the high-risk papillomas.
Transforming growth factor (1 (TGF-,B1) and TGF-f82 are 25 -kDa dimeric growth-regulatory proteins (6) that act as potent growth inhibitors for normal and initiated keratinocytes in vitro (7) . TGF-f31 protein is increased suprabasally in the mouse epidermis after a single PMA treatment (8, 9) and in human epidermis after wounding (10) . TGF-(82 is expressed by differentiating keratinocytes both in vitro (11) and in vivo (7) 
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skin. Carcinomas were isolated from animals after >30 weeks of promotion from these and similar tumor-induction experiments.
TGF-P Immunodetection. Immunodetection of TGF-P on 5-,um frozen sections was done without hyaluronidase treatment, by using Vectastain Elite (Vector Laboratories) and Histomark Orange metal-enhanced diaminobenzidine (Kirkegaard and Perry Laboratories, Gaithersburg, MD) stains. Sections were counterstained with Mayer's hematoxylin. TGF-,81 antibodies were anti-CC(1-30-1), which is directed against a peptide in the mature TGF-pl and detects predominantly the extracellular molecule (13) , and antipre(266-278-1), which recognizes a peptide in the precursor domain (14) . Staining occurred with anti-CC(1-30-1) in tumors when frozen sections were pretreated briefly in Bouin's fixative. TGF-f32 antibodies were anti-LC(50-75-2) (15) and anti-352-376 (Santa Cruz Biotech), both directed against peptides in the mature TGF-/32 molecule, and anti-pre(197-212-2), directed against a peptide in the TGF-(32 precursor domain. Similar staining was seen with antibodies to both the precursor and the mature TGF-132 molecule. All TGF-P antibodies were used at 2 ,ug/ml. Immunohistochemical analysis of low-and high-risk groups was done simultaneously with identical development times and repeated at least three times. Negative staining was judged against sections incubated with corresponding blocking peptide and normal skin controls. Results were confirmed by indirect immunofluorescence. All photomicrographs were taken with a Zeiss Axiophot microscope.
BrdUrd Labeling and Detection. One hour prior to sacrifice mice were injected with BrdUrd (0.2 mg/g) in saline (0.9%o NaCl, 300 A1). BrdUrd incorporation was localized on serial frozen sections of papillomas previously characterized for TGF-,3 expression by using a monoclonal anti-BrdUrd antibody (Becton Dickinson) and horseradish peroxidase-labeled second antibody (16) . The labeling index was calculated from enlargements of low-power photomicrographs as the number of BrdUrd-positive cells in either the basal or suprabasal compartments per total basal nuclei. Regions containing 100-300 total basal cells were used for each count.
Keratin Immunodetection. Keratin expression was localized on serial frozen sections by using monospecific rabbit antibodies to keratins 1, 10, and 13 (17) .
In Situ Hybridization. Frozen sections (5 ,um) of week 22 papillomas were prepared for hybridization, prehybridized, and hybridized in situ (18) to 35S-labeled TGF-,32 antisense and sense RNA probes (2 x 107 cpm/ml) generated from a fragment of the mouse TGF-,82 coding sequence subcloned in pBluescript KS (Stratagene) (19) . Sections were hybridized for 4 hr at 52°C in hybridization solution as described (18) . The sections were rinsed and treated with RNases A and Ti for 30 min at 37°C, subjected to a final wash in 30mM NaCl/3 mM sodium citrate, pH 7/50%o (vol/vol) formamide at 60°C for 15 min, and processed for autoradiography with Kodak NBT-2 emulsion. Slides were exposed 12 days and examined under dark-field conditions with a Zeiss Axiophot microscope.
PCR Analysis of TGF-fl-Nufl Mice. Targeted deletion of TGF-f31 was done with replacement vectors as described (12) . Genotypes were determined from PCR analysis of tail DNA. Wild-type alleles were identified with a primer pair from the first exon and intron of the mouse TGF-,11 gene (5'-CGTGCGCCTGTCGCTTTCTG-3' and 5'-GCGGAC-TACTATGCTAAAG-3'). Null alleles were identified with a primer from exon 1 of the TGF-(31 locus (5'-AGGGAGCTG-GTGAAACGGAA-3') and from the phosphoglycerate kinase 1 promoter of the neomycin-resistance cassette (5'-TCCATCTGCACGAGACTAGT-3'). The PCR mixture contained 3 mM Mg2+, and the annealing temperature was 600C.
RESULTS
Compartmentalized Expression of TGF-fi in Normal Epidermis and Low-Risk Papiflomas. TGF-,B1 and TGF-132 were localized on frozen sections with specific anti-peptide polyclonal antibodies directed against either the mature or the precursor region of the TGF-f3 molecule. TGF-j31 was present exclusively in the basal layer of normal mouse epidermis, whereas TGF-P2 was exclusive to the suprabasal differentiating layers (Fig. 1 a and b) . A similar pattern was found in epidermis chronically treated with PMA ( Fig. 1 dand  e) . Benign papillomas with a low risk for malignant conversion (4) were generated with DMBA initiation and continuous PMA promotion. This protocol generates a few papillomas between weeks 6 and 8 which are the high-risk type and a large number of papillomas between weeks 9 and 11 which are of the low-risk type. At 11 weeks from the onset of promotion, all papillomas were isolated from several animals; 90% of these tumors appeared between weeks 9 and 11. Eleven of 13 (85%) of these predominantly low-risk tumors had compartmentalized TGF-l3 expression identical to that found in normal epidermis ( Fig. 1 (Fig. 2) . Similar results were obtained for TGF-p1 in dysplastic papillomas and carcinomas (9) , suggesting that a posttranscriptional block of expression is responsible for loss of both isoforms in high-risk papillomas and carcinomas.
We examined keratin expression in the high-risk papillomas to relate loss of TGF-P expression to other biochemical changes relevant for tumor progression. Keratins 1 and 10, expressed in the differentiating layers of normal epidermis, are lost during tumor progression and commonly replaced by keratin 13 (16, 17) . Nearly all of the early TGF-,B-positive papillomas expressed keratins 1 and 10 but not keratin 13, whereas 10 of 14 of the 8-week TGF-,B-deficient papillomas expressed keratin 13 and had reduced or absent keratins 1 and 10 ( Fig. 1) . Thus, loss of TGF-l3 is associated with early (20) . In 11-week low-risk TGF-(3-positive papillomas, the labeling index increased 3-to 4-fold, but only 11% of the proliferating cells were suprabasal (Fig. 3) . In high-risk papillomas where TGF-p81 was reduced or absent but TGF-l32 was highly expressed, the labeling index was further increased, but only 17% of the proliferating cells were in the suprabasal layer (Fig. 3) . However, in high-risk papillomas where both isoforms were absent, the total labeling index increased to 66%, and 40% of the proliferating cells were in the suprabasal compartment. This represents a 25-fold increase in suprabasal proliferation compared with TGF-3-positive papillomas (Fig. 3) . Thus the expansion of the proliferative compartment, a hallmark of tumor progression, occurs early in high-risk papillomas and is directly related to altered TGF-p2 synthesis.
Epidermal Hyperproliferation in TGF-fl. focal loss of TGF-l3 in most papillomas subject to long-term promotion supports the concept of similar pathways of progression in all tumors (23) , but at vastly different rates.
The inverse relationship of TGF-l3 expression to labeling index in papillomas and TGF-811-null mice and the low level of suprabasal proliferation in TGF-31-deficient papillomas suggest that the action of each isoform is compartmentalized along with expression and that distant paracrine influences are marginal. TGF-,l3 is likely to be a negative regulator of proliferation in the basal layer, while TGF-p82 may act to inhibit DNA synthesis or induce apoptosis (24, 25) in the suprabasal terminally differentiating compartment. Since the TGF-,31-null epidermis has a TGF-f phenotype similar to that found in some papillomas, factors in addition to hyperproliferation, such as altered differentiation, must be responsible for the hyperplasia found in papillomas (26) .
The uncoupling of isoform loss in certain papillomas suggests that loss of TGF-f31 may be the initial alteration, and 8 expression has been observed in several cell culture systems (7, 27) and has been reported for TGF-,B1 in dysplastic papillomas and carcinomas (9) . While both low-and high-risk papillomas initiated with DMBA have identical ras mutations (28), high-level expression of the v-Ha-ras oncogene in cultured keratinocytes is sufficient to cause a posttranscriptional block of TGF-t32 expression (7). Thus differences in expression levels of the mutant Ha-ras allele between lowand high-risk papillomas could contribute to this phenotype.
These data support the concept that TGF-,3 is an antipromoter in this tissue (7, 9) . Reduced expression of both TGF-j3 isoforms in papillomas compared to normal skin or chronically promoter-treated skin indicates that papillomatous outgrowth requires an altered balance between positive and negative growth signals (7, 29) . The extent of expression of TGF-f3 in expanding initiated clones could explain the growth properties and promotion requirements ofdifferent papilloma populations. Previous, studies (30) (31) (32) (33) , and the benign histology of high-risk papillomas, indicate that multiple genetic changes in papillomas are required for malignant conversion. Documented effects of the TGF-(3 family on metalloproteinase expression (6) and suppression of tumorigenesis (21, 34) suggest that absence of TGF-P could contribute directly to the malignant phenotype. Additionally, aneuploidy and specific oncogenic changes due to chromosome instability are characteristic ofprogression in epidermal carcinogenesis (23, 31, 35) . Although specific mutations may be required to create an unstable genome, it is possible that the increased cell proliferation in TGF-3-deficient papillomas enhances the probability for generation of aneuploid clones, producing some with changes relevant for malignancy. The enhanced sensitivity ofhigh-risk papillomas to malignant conversion by additional carcinogen treatment (28) supports this hypothesis.
